Product Information
SOFOSBUVIR-VELPATASVIR 400-100 is a generic product labeled by Asegua Therapeutics LLC, priced at $278.0258 per EA under NDC 72626270101. Its NADAC has been published 276 times since Nov 18, 2020.
FDA first approved this application on Jun 28, 2016.
Strength
400; 100 mg/1; mg/1
Manufacturer
Asegua Therapeutics LLCNDC
72626270101
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
SOFOSBUVIR; VELPATASVIRApproval Type
Authorized Generic (NDA)
FDA Application
NDA208341FDA Approved
6/28/2016
On Market Since
11/14/2018
Pharmacological Classes
Price Statistics
The NADAC for SOFOSBUVIR-VELPATASVIR 400-100 has been published 276 times since Nov 18, 2020, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $278.0258 per EA |
|---|---|
| All-time high | $282.8571 (Nov 10, 2021) |
| All-time low | $276.8074 (Jan 22, 2025) |
| 52-week high | $278.3390 |
| 52-week low | $278.0258 |
| Median price | $278.3429 |
| Average price | $278.9686 |
| Largest weekly change | -1.5% (Jun 22, 2022) |
| Weeks tracked | 276 |
| Tracking since | Nov 18, 2020 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Asegua Therapeutics LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Velpatasvir and Sofosbuvir market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Hepatitis C Virus NS5A Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of SOFOSBUVIR-VELPATASVIR 400-100?
The current National Average Drug Acquisition Cost (NADAC) for SOFOSBUVIR-VELPATASVIR 400-100, manufactured by Asegua Therapeutics LLC, is $278.0258 per EA (NDC 72626270101), effective Sep 30, 2026.
How has the price of SOFOSBUVIR-VELPATASVIR 400-100 changed over time?
Over the history we have for it, the NADAC for SOFOSBUVIR-VELPATASVIR 400-100 has held within roughly two percent of its current level. It has been tracked across 276 weekly CMS publications since Nov 18, 2020.
What are the highest and lowest recorded NADAC prices for SOFOSBUVIR-VELPATASVIR 400-100?
Since Nov 18, 2020, the NADAC for SOFOSBUVIR-VELPATASVIR 400-100 has ranged from a low of $276.8074 (Jan 22, 2025) to a high of $282.8571 (Nov 10, 2021), with a median of $278.3429 per EA.
Are there cheaper alternatives to SOFOSBUVIR-VELPATASVIR 400-100?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as SOFOSBUVIR-VELPATASVIR 400-100 in a comparable dosage form, but none are currently priced below it.
Who manufactures SOFOSBUVIR-VELPATASVIR 400-100?
SOFOSBUVIR-VELPATASVIR 400-100 (NDC 72626270101) is labeled by Asegua Therapeutics LLC, and CMS classifies it as a generic product.